Simultaneously, downregulating mouse double minute 2 (MDM2) could restore the sensitivity of GC cells to apatinib and counteract the resistance mediated by ESPL1. Recent clinical studies confirm a critical role for the BRD4/ALKBH5/ESPL1 pathway in BC progression (Zhang et al., 2025). Here, MDM2 is linked to breast cancer.